Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: A randomized controlled study

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Lee, Yong Kyu ^a   Lee, Hae Won ^b   Choi, Kyu Hun ^b   Kim, Beom Seok ^b  

^a National Health Insurance Corporation   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

NAFAMSTAT MESILATE; ANTICOAGULANT AGENT; GUANIDINE DERIVATIVE; NAFAMSTAT;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GYNECOLOGIC DISEASE; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HUMAN; INFECTION; KIDNEY DISEASE; LIFESPAN; LUNG DISEASE; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROLOGIC DISEASE; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; SURVIVAL RATE; TREATMENT OUTCOME; VAGINA BLEEDING; ACUTE KIDNEY INJURY; ADVERSE EFFECTS; BLOOD TRANSFUSION; CHEMICALLY INDUCED; DEVICES; MIDDLE AGED; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY;

ACUTE KIDNEY INJURY; ADULT; AGED; ANTICOAGULANTS; BLOOD TRANSFUSION; FEMALE; GUANIDINES; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL REPLACEMENT THERAPY;

EID: 84907847994     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108737     Document Type: Article

References (31)

1. Schetz M, Lauwers PM, Ferdinande P (1989) Extracorporeal treatment of acute renal failure in the intensive care unit: a critical view. Intensive care medicine 15: 349-357.
2. Tolwani AJ, Wille KM (2009) Anticoagulation for continuous renal replacement therapy. Seminars in dialysis 22: 141-145.
3. Tolwani A, Wille KM (2012) Regional citrate anticoagulation for continuous renal replacement therapy: the better alternative? American journal of kidney diseases: the official journal of the National Kidney Foundation 59: 745-747.
4. van de Wetering J, Westendorp RG, van der Hoeven JG, Stolk B, Feuth JD, et al. (1996) Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. Journal of the American Society of Nephrology: JASN 7: 145-150.
5. van der Voort PH, Gerritsen RT, Kuiper MA, Egbers PH, Kingma WP, et al. (2005) Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation. Blood purification 23: 175-180.
6. Reeves JH, Cumming AR, Gallagher L, O'Brien JL, Santamaria JD (1999) A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Critical care medicine 27: 2224-2228.
7. Journois D, Safran D, Castelain MH, Chanu D, Drevillon C, et al. (1990) [Comparison of the antithrombotic effects of heparin, enoxaparin and prostacycline in continuous hemofiltration]. Annales francaises d'anesthesie et de reanimation 9: 331-337.
8. Ohtake Y, Hirasawa H, Sugai T, Oda S, Shiga H, et al. (1991) Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration. Contributions to nephrology 93: 215-217.
9. Akizawa T, Koshikawa S, Ota K, Kazama M, Mimura N, et al. (1993) Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding. Nephron 64: 376-381.
10. Hitomi Y, Ikari N, Fujii S (1985) Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis 15: 164-168.
11. Baek NN, Jang HR, Huh W, Kim YG, Kim DJ, et al. (2012) The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding. Renal failure 34: 279-285.
12. Maruyama Y, Yoshida H, Uchino S, Yokoyama K, Yamamoto H, et al. (2011) Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study. The International journal of artificial organs 34: 571-576.
13. Hwang SD, Hyun YK, Moon SJ, Lee SC, Yoon SY (2013) Nafamostat mesilate for anticoagulation in continuous renal replacement therapy. The International journal of artificial organs 36: 208-216.
14. Lindquist M, Stahl M, Bate A, Edwards IR, Meyboom RH (2000) A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug safety: an international journal of medical toxicology and drug experience 23: 533-542.
15. National Cancer Institute NIoH, US department of Health and Human Service Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Available: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf. Accessed 2014 Sept 12.
16. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, et al. (2001) Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119: 64S-94S.
17. Horrow JC (1985) Protamine: a review of its toxicity. Anesthesia and analgesia 64: 348-361.
18. Meier-Kriesche HU, Gitomer J, Finkel K, DuBose T (2001) Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation. Critical care medicine 29: 748-752.
19. Khwaja A (2012) KDIGO Clinical Practice Guidelines for Acute Kidney Injury. Nephron. Clinical practice 120: 179-184.
20. Morabito S, Pistolesi V, Tritapepe L, Zeppilli L, Polistena F, et al. (2012) Regional citrate anticoagulation in cardiac surgery patients at high risk of bleeding: a continuous veno-venous hemofiltration protocol with a low concentration citrate solution. Critical care 16: R111.
21. Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, et al. (2004) Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive care medicine 30: 260-265.
22. Kutsogiannis DJ, Gibney RT, Stollery D, Gao J (2005) Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney international 67: 2361-2367.
23. Hetzel GR, Schmitz M, Wissing H, Ries W, Schott G, et al. (2011) Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 26: 232-239.
24. Wu MY, Hsu YH, Bai CH, Lin YF, Wu CH, et al. (2012) Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a metaanalysis of randomized controlled trials. American journal of kidney diseases: the official journal of the National Kidney Foundation 59: 810-818.
25. Oudemans-van Straaten HM, Bosman RJ, Koopmans M, van der Voort PH, Wester JP, et al. (2009) Citrate anticoagulation for continuous venovenous hemofiltration. Critical care medicine 37: 545-552.
26. Meier-Kriesche HU, Finkel KW, Gitomer JJ, DuBose TD Jr (1999) Unexpected severe hypocalcemia during continuous venovenous hemodialysis with regional citrate anticoagulation. American journal of kidney diseases: the official journal of the National Kidney Foundation 33: e8.
27. Oudemans-van Straaten HM, Ostermann M (2012) Bench-to-bedside review: Citrate for continuous renal replacement therapy, from science to practice. Critical care 16: 249.
28. Nakae H, Tajimi K (2003) Pharmacokinetics of nafamostat mesilate during continuous hemodiafiltration with a polyacrylonitrile membrane. Therapeutic apheresis and dialysis: official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 7: 483-485.
29. Okada H, Suzuki H, Deguchi N, Saruta T (1992) Agranulocytosis in a haemodialysed patient induced by a proteinase inhibitor, nafamostate mesilate. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 7: 980.
30. Ookawara S, Tabei K, Sakurai T, Sakairi Y, Furuya H, et al. (1996) Additional mechanisms of nafamostat mesilate-associated hyperkalaemia. European journal of clinical pharmacology 51: 149-151.
31. Higuchi N, Yamazaki H, Kikuchi H, Gejyo F (2000) Anaphylactoid reaction induced by a protease inhibitor, nafamostat mesilate, following nine administrations in a hemodialysis patient. Nephron 86: 400-401.